

SUPPLEMENTAL TABLE 2 (continued)

FDA-APPROVED THERAPEUTICS FOR THE TREATMENT OF CANCER

DNA Repair Inhibitors

Approved Indication	Generic Name	Trade Name
certain types of ovarian, fallopian tube, and primary peritoneal cancers	niraparib	Zejula
certain forms of breast and ovarian cancers	olaparib*	Lynparza
certain type of ovarian cancer	rucaparib*	Rubraca
certain type of breast cancer	talazoparib*	Talzenna

Immune Checkpoint Inhibitors

Approved Indication	Generic Name	Trade Name
certain types of bladder, breast, and lung cancers	atezolizumab	Tecentriq
certain types of bladder, kidney, and skin cancers	avelumab	Bavencio
certain type of skin cancer	cemiplimab-rwlc	Libtayo
certain types of bladder cancer and lung cancer	durvalumab	Imfinzi
multiple cancers	ipilimumab	Yervoy
multiple cancers	nivolumab	Opdivo
multiple cancers	pembrolizumab	Keytruda

Bone-remodeling Inhibitors

Approved Indication	Generic Name	Trade Name
potentially lethal complication of advanced cancers*	denosumab	Xgeva

Angiogenesis Inhibitors

Approved Indication	Generic Name	Trade Name
kidney cancer	axitinib	Inlyta
multiple cancers	bevacizumab	Avastin
thyroid cancer; kidney cancer; liver cancer	cabozantinib	Cometriq; Cabometyx
certain type of thyroid cancer; kidney cancer; liver cancer	lenvatinib	Lenvima
kidney cancer; soft tissue sarcomas; gastrointestinal stromal tumors	pazopanib	Votrient
certain types of lung, stomach, and liver cancers	ramucirumab	Cyramza

colorectal cancer; gastrointestinal stromal tumors and liver cancer	regorafenib	Stivarga
kidney cancer; certain type of thyroid cancer	sorafenib	Nexavar
gastrointestinal stromal tumors; kidney cancer; some pancreatic cancers	sunitinib	Sutent
thyroid cancer	vandetanib	Caprelsa
colorectal cancer	ziv-aflibercept	Zaltrap

Cell Lysis Mediators

Approved Indication	Generic Name	Trade Name
certain leukemias	alemtuzumab	Campath
certain types of leukemia	blinatumomab	Blincyto
certain lymphomas	brentuximab vedotin	Adcetris
multiple myeloma	daratumumab	Darzalex
neuroblastoma	dinutuximab	Unituxin
multiple myeloma	elotuzumab	Empliciti
certain lymphomas	ibritumomab	Zevalin
certain types of non-Hodgkin lymphoma	mogamulizumab-kpkc	Poteligeo
certain type of leukemia	moxetumomab pasudotox-tdfk	Lumoxiti
certain form of leukemia; certain form of lymphoma	obinutuzumab	Gazyva
certain leukemias	ofatumumab	Arzerra
certain lymphomas	rituximab	Rituxan
certain type of leukemia	tagraxofusp-erzs	Elzonris

Oncolytic Virus

Approved Indication	Generic Name	Trade Name
melanoma	talimogene laherparepvec	Imlygic

Therapeutic Vaccines

Approved Indication	Generic Name	Trade Name
prostate cancer	sipuleucel-T	Provenge

CAR T-cell Therapy

Approved Indication	Generic Name	Trade Name
certain type of non-Hodgkin lymphoma	axicabtagene ciloleucel	Yescarta
certain types of leukemia and non-Hodgkin lymphoma	tisagenlecleucel	Kymriah

INCREASING PRECISION

* includes companion diagnostic

Some drugs are available in multiple formulations; these have only been listed once. Where multiple trade names are used, only the most common have been listed.

American Association for Cancer Research
(AACR) Cancer Progress Report 2019